Brad Loncar discusses the rallies in both Moderna and Regeneron following their quarterly results. Moderna's earnings and revenue blew past expectation, despite the company warning of declining profit as a result of unused Covid-19 vaccines. Regeneron also beat on top and bottom line, amid record sales of several of its products. Tom White then breaks down a bullish example trade in Moderna and a neutral to bullish trade in Regeneron.
04 Aug 2022
Morning Trade Live
07 Nov 2022
Market On Close
10 Jan 2023
Market On Close
31 Jan 2023
The Watch List
22 Jan 2023
Trading 360
07 Dec 2022
The Watch List
09 Dec 2022